\-\ Texto\\:\\ \ \(0\)\
\-\ none\ \(204\)\
\-\ correct\\ hypophosphatemia\\ and\\ \\/\\ or\\ vit\\ d\\ abnormalities\\.\ \(0\)\
\-\ distal\\ femoral\\ metaphyseal\\ widening\\,\\ fraying\\ and\\ cupping\\.\ \(0\)\
\-\ rickets\ \(46\)\
\-\ 1\\.\\ \\ abnormal\\ vitamin\\ d\\ metabolism\\ secondary\\ to\\;\\ deficiency\\,\\ malabsorption\\,\\ inadequate\\ dietary\\ intake\\,\\ inadequate\\ sunlight\\ \ \(0\)\
\-\ 2\\.\\ hepatic\\ origin\\:\\ anticonvulsant\\ therapy\\ \\(increased\\ hepatic\\ metabolism\\)\\,\\ liver\\ disease\\ \\(failure\\ of\\ 25\\ hydroxylation\\)\\ \ \(0\)\
\-\ 3\\.\\ vit\\ d\\ dependent\\ rickets\\ \ \(0\)\
\-\ 4\\.\\ parathyroid\\ disorders\\ \\(hypo\\,\\ hyper\\,\\ pseudohypo\\)\ \(1\)\
\-\ 5\\.\\ maternal\\ renal\\ insufficiency\\ as\\ a\\ cause\\ of\\ congenital\\ rickets\\ and\\ secondary\\ hyperparathyroidism\\.\\ \ \(1\)\
\-\ 6\\.\\ phosphate\\ loss\\ due\\ to\\ renal\\ tubular\\ disorders\\ \ \(0\)\
\-\ 7\\.\\ vit\\ d\\ resistant\\ rickets\\:\\ x\\-linked\\ hypophosphatemia\\ \ \(0\)\
\-\ 8\\.\\ fanconi\\ syndrome\\ \ \(0\)\
\-\ 9\\.\\ renal\\ tubular\\ acidosis\\ \ \(1\)\
\-\ 10\\.\\ tumor\\ related\\ \\-hemangiomas\\ of\\ the\\ bone\\ or\\ soft\\ tissue\\ \\-metastatic\\ neuroblastoma\\ dietary\\ calcium\\ deficiency\ \(0\)\
\-\ one\\ and\\ a\\ half\\ year\\ old\\ with\\ short\\ stature\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ rickets\\:\\ 0\\.15945277687352155\ \(0\)\
\-\ vit\\:\\ 0\\.152657961664693\ \(0\)\
\-\ d\\:\\ 0\\.1262708602182506\ \(0\)\
\-\ hypophosphatemia\\:\\ 0\\.10675674831899849\ \(0\)\
\-\ dietary\\:\\ 0\\.08480705141641752\ \(0\)\
\-\ inadequate\\:\\ 0\\.0841485067857385\ \(0\)\
\-\ metabolism\\:\\ 0\\.0823321760880743\ \(0\)\
\-\ deficiency\\:\\ 0\\.06830853043815605\ \(0\)\
\-\ disorders\\:\\ 0\\.06056489785561715\ \(0\)\
\-\ hydroxylation\\:\\ 0\\.060165712914122614\ \(0\)\
\-\ pseudohypo\\:\\ 0\\.060165712914122614\ \(0\)\
\-\ \\-hemangiomas\\:\\ 0\\.060165712914122614\ \(0\)\
\-\ tubular\\:\\ 0\\.05895165210392623\ \(0\)\
\-\ sunlight\\:\\ 0\\.05716226766887695\ \(0\)\
\-\ fanconi\\:\\ 0\\.05716226766887695\ \(0\)\
\-\ renal\\:\\ 0\\.05705501221017932\ \(0\)\
\-\ hepatic\\:\\ 0\\.0528665829897187\ \(0\)\
\-\ hypo\\:\\ 0\\.04902439886392799\ \(0\)\
\-\ x\\-linked\\:\\ 0\\.04902439886392799\ \(0\)\
\-\ malabsorption\\:\\ 0\\.04824395059979594\ \(0\)\
\-\ anticonvulsant\\:\\ 0\\.04824395059979594\ \(0\)\
\-\ phosphate\\:\\ 0\\.04753794926791206\ \(0\)\
\-\ fraying\\:\\ 0\\.045240505354550285\ \(0\)\
\-\ cupping\\:\\ 0\\.045240505354550285\ \(0\)\
\-\ hyper\\:\\ 0\\.045240505354550285\ \(0\)\
\-\ \\-metastatic\\:\\ 0\\.045240505354550285\ \(0\)\
\-\ stature\\:\\ 0\\.04476244223501272\ \(0\)\
\-\ resistant\\:\\ 0\\.04274811841661537\ \(0\)\
\-\ acidosis\\:\\ 0\\.040886530058979034\ \(0\)\
\-\ parathyroid\\:\\ 0\\.04010608179484698\ \(0\)\
\-\ maternal\\:\\ 0\\.03986319421838039\ \(0\)\
\-\ 10\\.\\:\\ 0\\.03917894740259509\ \(0\)\
\-\ intake\\:\\ 0\\.038964224907237666\ \(0\)\
\-\ metaphyseal\\:\\ 0\\.03779219523897919\ \(0\)\
\-\ vitamin\\:\\ 0\\.037269102148505456\ \(0\)\
\-\ correct\\:\\ 0\\.037102636549601324\ \(0\)\
\-\ 9\\.\\:\\ 0\\.037102636549601324\ \(0\)\
\-\ secondary\\:\\ 0\\.035393036540871226\ \(0\)\
\-\ 8\\.\\:\\ 0\\.03535160856394036\ \(0\)\
\-\ dependent\\:\\ 0\\.03415426521907802\ \(0\)\
\-\ 7\\.\\:\\ 0\\.033724729977223575\ \(0\)\
\-\ insufficiency\\:\\ 0\\.0336211281848181\ \(0\)\
\-\ half\\:\\ 0\\.033418172820461695\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.03322063024948272\ \(0\)\
\-\ widening\\:\\ 0\\.03188636235147888\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.031646101049603664\ \(0\)\
\-\ \\/\\:\\ 0\\.03126221165801414\ \(0\)\
\-\ calcium\\:\\ 0\\.03096881063508787\ \(0\)\
\-\ 6\\.\\:\\ 0\\.0307561431841069\ \(0\)\
\-\ short\\:\\ 0\\.029837234675440392\ \(0\)\
\-\ origin\\:\\ 0\\.02901984165937472\ \(0\)\
\-\ 5\\.\\:\\ 0\\.027300886733655\ \(0\)\
\-\ related\\:\\ 0\\.026127788098310838\ \(0\)\
\-\ 25\\:\\ 0\\.025586861172274614\ \(0\)\
\-\ 4\\.\\:\\ 0\\.024922073854820724\ \(0\)\
\-\ failure\\:\\ 0\\.024795987280232346\ \(0\)\
\-\ femoral\\:\\ 0\\.02408146678995411\ \(0\)\
\-\ abnormalities\\:\\ 0\\.02325010830887568\ \(0\)\
\-\ congenital\\:\\ 0\\.023149325701055094\ \(0\)\
\-\ liver\\:\\ 0\\.021823863043205362\ \(0\)\
\-\ 3\\.\\:\\ 0\\.02165832749733872\ \(0\)\
\-\ cause\\:\\ 0\\.02141676019668123\ \(0\)\
\-\ 2\\.\\:\\ 0\\.020129215865187098\ \(0\)\
\-\ 1\\.\\:\\ 0\\.01977177160220445\ \(0\)\
\-\ loss\\:\\ 0\\.018373808684951403\ \(0\)\
\-\ syndrome\\:\\ 0\\.018103011679515862\ \(0\)\
\-\ abnormal\\:\\ 0\\.018052535113443787\ \(0\)\
\-\ distal\\:\\ 0\\.017209471029229827\ \(0\)\
\-\ one\\:\\ 0\\.01715356580230107\ \(0\)\
\-\ therapy\\:\\ 0\\.016923265157337875\ \(0\)\
\-\ due\\:\\ 0\\.016890941873724738\ \(0\)\
\-\ \\:\\:\\ 0\\.016744812088750595\ \(0\)\
\-\ \\(\\:\\ 0\\.016052482805419124\ \(0\)\
\-\ \\)\\:\\ 0\\.015856393158073447\ \(0\)\
\-\ bone\\:\\ 0\\.01572914578859163\ \(0\)\
\-\ none\\:\\ 0\\.015701625977096345\ \(0\)\
\-\ increased\\:\\ 0\\.015485072457775228\ \(0\)\
\-\ soft\\:\\ 0\\.015414272325878149\ \(0\)\
\-\ \\;\\:\\ 0\\.015003119914463658\ \(0\)\
\-\ tissue\\:\\ 0\\.015003119914463658\ \(0\)\
\-\ or\\:\\ 0\\.014837374058721594\ \(0\)\
\-\ tumor\\:\\ 0\\.014757276308228233\ \(0\)\
\-\ \\,\\:\\ 0\\.014036818212007493\ \(0\)\
\-\ disease\\:\\ 0\\.010346204009005216\ \(0\)\
\-\ as\\:\\ 0\\.009574648191808354\ \(0\)\
\-\ year\\:\\ 0\\.0070822612538734425\ \(0\)\
\-\ old\\:\\ 0\\.006480997013794479\ \(0\)\
\-\ to\\:\\ 0\\.006326934939896093\ \(0\)\
\-\ a\\:\\ 0\\.005875552619534834\ \(0\)\
\-\ and\\:\\ 0\\.00533360016984351\ \(0\)\
\-\ of\\:\\ 0\\.0025889733510664095\ \(0\)\
\-\ \\.\\:\\ 0\\.001051838106588038\ \(0\)\
\-\ the\\:\\ 0\\.0010240687755824133\ \(0\)\
\-\ with\\:\\ 0\\.0008666976006658499\ \(0\)\
